Blarcamesine Improves Symptoms for Patients with Parkinson Disease Dementia,

The full results from the proof-of-concept phase 2 study of blarcamesine suggests the drug’s impact on increasing sigma-1 receptor (SIGMAR1) mRNA …, The full results from the proof-of-concept phase 2 study of blarcamesine suggests the drug’s impact on increasing sigma-1 receptor (SIGMAR1) mRNA …, Read More

Scroll to Top